JP5222134B2 - Ｈｅｒ−２ペプチド - Google Patents

Ｈｅｒ−２ペプチド Download PDF

Info

Publication number
JP5222134B2
JP5222134B2 JP2008517193A JP2008517193A JP5222134B2 JP 5222134 B2 JP5222134 B2 JP 5222134B2 JP 2008517193 A JP2008517193 A JP 2008517193A JP 2008517193 A JP2008517193 A JP 2008517193A JP 5222134 B2 JP5222134 B2 JP 5222134B2
Authority
JP
Japan
Prior art keywords
epitope
chimeric peptide
peptide
linker
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008517193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500298A5 (enExample
JP2009500298A (ja
Inventor
プラビン ティー． ピー． カウマヤ，
Original Assignee
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション filed Critical ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション
Publication of JP2009500298A publication Critical patent/JP2009500298A/ja
Publication of JP2009500298A5 publication Critical patent/JP2009500298A5/ja
Application granted granted Critical
Publication of JP5222134B2 publication Critical patent/JP5222134B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008517193A 2005-06-15 2006-06-15 Ｈｅｒ−２ペプチド Expired - Fee Related JP5222134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69057405P 2005-06-15 2005-06-15
US60/690,574 2005-06-15
PCT/US2006/023672 WO2006138675A2 (en) 2005-06-15 2006-06-15 Her-2 peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012093680A Division JP5542865B2 (ja) 2005-06-15 2012-04-17 Ｈｅｒ−２ペプチド

Publications (3)

Publication Number Publication Date
JP2009500298A JP2009500298A (ja) 2009-01-08
JP2009500298A5 JP2009500298A5 (enExample) 2009-07-30
JP5222134B2 true JP5222134B2 (ja) 2013-06-26

Family

ID=37571268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008517193A Expired - Fee Related JP5222134B2 (ja) 2005-06-15 2006-06-15 Ｈｅｒ−２ペプチド
JP2012093680A Expired - Fee Related JP5542865B2 (ja) 2005-06-15 2012-04-17 Ｈｅｒ−２ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012093680A Expired - Fee Related JP5542865B2 (ja) 2005-06-15 2012-04-17 Ｈｅｒ−２ペプチド

Country Status (7)

Country Link
US (3) US7691396B2 (enExample)
EP (1) EP1912680B1 (enExample)
JP (2) JP5222134B2 (enExample)
AU (1) AU2006261342B2 (enExample)
CA (1) CA2612394C (enExample)
ES (1) ES2531483T3 (enExample)
WO (1) WO2006138675A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
WO2006138675A2 (en) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Her-2 peptides
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2008097229A1 (en) * 2007-02-09 2008-08-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Method for spectroscopic quantitation of her-2 in biological samples
JP5269186B2 (ja) * 2008-04-22 2013-08-21 ロックウッド・リチウム・インコーポレイテッド 高純度水酸化リチウムと塩酸とを製造する方法
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US9125848B2 (en) 2010-06-10 2015-09-08 The Cleveland Clinic Foundation Alpha lactalbumin immunization methods
RU2607033C2 (ru) * 2010-09-28 2017-01-10 Ноно Инк. Пептиды nd2 и способы лечения неврологического заболевания
RU2645085C2 (ru) 2012-04-16 2018-02-15 Дзе Кливленд Клиник Фаундейшн Мультивалентная вакцина против рака молочной железы
WO2014131019A2 (en) 2013-02-25 2014-08-28 Ohio State Innovation Foundation Her-1, her-3 and igf-1r compositions and uses thereof
CN105017425B (zh) * 2014-04-30 2018-02-16 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
WO2017078761A2 (en) * 2015-11-06 2017-05-11 Evorx Technologies, Inc. Her-2-specific cyclized supr peptides
WO2018145020A1 (en) 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CA3058393A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
US20200179500A1 (en) * 2018-12-05 2020-06-11 Wayne State University Methods and immunogenic compositions relating to her2 with selective sequence modifications
US20220169747A1 (en) * 2019-03-22 2022-06-02 Olivia Newton-John Cancer Research Institute Anti-her2 binding molecules
AU2020350666A1 (en) * 2019-09-17 2022-03-31 Ohio State Innovation Foundation Human anti-PD-L1 peptide vaccines and methods of their use
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
CN119019569B (zh) * 2024-08-19 2025-10-24 中国人民解放军陆军军医大学 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
CA2074720C (en) * 1990-01-26 2002-07-23 Martin A. Cheever Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
AU687750B2 (en) 1992-09-28 1998-03-05 Wyeth Holdings Corporation Method of enhancing cell mediated immune responses
CA2145391A1 (en) 1992-09-30 1994-04-14 Vernon C. Stevens Vaccines and antigenic conjugates
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
NZ331596A (en) * 1996-04-03 1999-07-29 Pepresearch A S Non-dendritic backbone peptide carrier
CN100415772C (zh) 1996-10-18 2008-09-03 基因技术股份有限公司 抗ErbB2抗体
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
AU738338B2 (en) 1997-08-11 2001-09-13 Allergan, Inc. Sterile bioerodible implant device with improved biocompatability and method
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP0953823A2 (en) 1998-05-01 1999-11-03 Aisin Cosmos R & D Co. Ltd. Micro yaw rate sensors
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
ES2320311T3 (es) * 1999-05-14 2009-05-21 Genentech, Inc. Tratamiento con anticuerpos anti-erbb2.
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
PL365789A1 (pl) * 2000-08-14 2005-01-10 Corixa Corporation Kompozycje oraz sposoby leczenia i diagnozowania nowotworów związanych z Her-2/neu
GB0213878D0 (en) * 2002-06-17 2002-07-31 Protherics Plc Use
WO2004030616A2 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
AU2004218284B2 (en) * 2003-03-04 2009-07-23 Intercell Ag Streptococcus pyogenes antigens
ATE463511T1 (de) * 2003-06-25 2010-04-15 Ottawa Hospital Res Inst Verwendung von cardiotrophin zur modulation der stammzellenproliferation
JP2008500015A (ja) * 2003-10-29 2008-01-10 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド 血管形成ペプチドおよびその使用
WO2005076972A2 (en) * 2004-02-05 2005-08-25 The Ohio State University Research Foundation Chimeric vegf peptides
SE527089C2 (sv) 2004-10-19 2005-12-20 Mia Kumm Anordning och system för ventilation av tunnel vid brand
BRPI0519172A2 (pt) * 2004-12-20 2008-12-30 Ajimoto Kk proteÍna mutante, polinucleotÍdeo, microorganismo transformado, e, mÉtodos de produzir uma proteÍna mutante, um peptÍdeo, e alfa-l-aspartil-l-fenilalanina-beta-Éster, e de projetar e produzir uma proteÍna mutante
WO2006138675A2 (en) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Her-2 peptides
US20100234283A1 (en) * 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP5510272B2 (ja) 2010-06-21 2014-06-04 株式会社リコー 画像形成装置

Also Published As

Publication number Publication date
WO2006138675A2 (en) 2006-12-28
US7691396B2 (en) 2010-04-06
EP1912680A2 (en) 2008-04-23
AU2006261342A1 (en) 2006-12-28
JP5542865B2 (ja) 2014-07-09
ES2531483T3 (es) 2015-03-16
EP1912680A4 (en) 2010-09-22
US20070060516A1 (en) 2007-03-15
CA2612394A1 (en) 2006-12-28
US9452204B2 (en) 2016-09-27
AU2006261342B2 (en) 2012-02-02
JP2012136555A (ja) 2012-07-19
US20140010831A1 (en) 2014-01-09
US8470333B2 (en) 2013-06-25
EP1912680B1 (en) 2014-11-26
CA2612394C (en) 2017-02-21
JP2009500298A (ja) 2009-01-08
US20110086055A1 (en) 2011-04-14
WO2006138675A9 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
JP5542865B2 (ja) Ｈｅｒ−２ペプチド
JP4658423B2 (ja) Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
US10166276B2 (en) Compositions and methods for treatment of non-hodgkins lymphoma
KR100731820B1 (ko) 치료적 백신화를 위한 새로운 방법
US20250059256A1 (en) Her-1, her-3 and igf-1r compositions and uses thereof
US9504738B2 (en) Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8080253B2 (en) Chimeric VEGF peptides
AU766898B2 (en) Tumor associated antigen 791Tgp72
JP2003529370A (ja) 血管浸透性に対する有害な作用を有さないｖｅ−カドヘリンに対する拮抗薬抗体
US7485621B2 (en) Tumor tag and the use thereof
US20210253646A1 (en) Vaccine vector encoding mutated gnaq for treatment of uveal melanoma and cancers having oncogenic mutations on gnaq and gna11 proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130308

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160315

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5222134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees